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Introduction: Activation of the PI3K/AKT pathway is a common phenomenon in cancer due to multiple
mechanisms, including mutation of PI3KCA, loss or mutation of PTEN, or over-expression of receptor tyrosine
kinases. We recently developed a novel AKT kinase inhibitor, AZD5363, and demonstrated that HGC27, a cell line
harboring both PI3KCA mutation and PTEN loss, displayed the greatest sensitivity to this AKT inhibitor in vitro and
in vivo.
Case preparation: To further elucidate the correlation between AZD5363 response and genetic alterations in
gastric cancer (GC) and identify GC patients with both PI3KCA mutations and PTEN loss, we investigated the effects
of pharmacological inhibition of AKT on a panel of 20 GC cell lines and genetic aberrations in tumor samples from
a cohort of Chinese GC patients. We demonstrated that GC cells with PI3KCA mutations were selectively sensitive
to AZD5363. Disease linkage studies showed that PI3KCA activating mutations or PTEN loss were found in 2.7%
(4/150) and 23% (14/61) of Chinese GC patients respectively. To further dissect the role of PI3KCA mutation and
PTEN loss in response to AKT inhibition, we tested the antitumor activity of AZD5363 in two patient-derived GC
xenograft (PDGCX) models harboring either PI3KCA mutation or PTEN loss. Our data indicated that AZD5363
monotherapy treatment led to a moderate response in the PI3KCA mutant PDGCX model. Whilst monotherapy
AZD5363 or Taxotere were ineffective in the PTEN negative PDGCX model, significant anti-tumor activity was
observed when AZD5363 was combined with Taxotere.
Conclusion: Our results indicated that PI3KCA mutation is an important determinant of response to AKT inhibition
in GC and combination with AZD5363 can overcome innate resistance to Taxotere in a PTEN loss PDGCX model. It
is suggested that AKT inhibitor is an attractive option for treatment of a new segment of GC patients with aberrant
PI3K/AKT signaling.Introduction
Gastric cancer (GC) is one of the most lethal malignancies
and the second leading cause of cancer death [1]. The esti-
mated global incidence and mortality of GC in 2011 were
990,000 and 737,000 cases respectively, accounting for
approximately 8% of total cancer cases and 10% of annual
cancer deaths worldwide [2]. Geographically, GC is far* Correspondence: yudehua@yahoo.com
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reproduction in any medium, provided the ormore prevalent in developing countries compared to
developed nations. Nations of high prevalence include
Eastern Asia, Central and Eastern Europe, and South
America, accounting for ~70% of the total cases. The con-
ventional treatments for GC include surgery, radiotherapy,
and chemotherapy [3]. Although these modalities are able
to prolong the overall survival of patients with early dis-
ease by 20-35%, they have very limited efficacy in treating
patients with advanced GC, conferring a median survival
time in the range of 6–11 months, with considerable
treatment-related toxicities [4]. Due to the complexity ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and the lower prevalence in western countries, the develop-
ment of targeted therapies for GC has lagged compared to
many other cancer indications. Overexpression/amplifica-
tion of Her2 has been observed in 10-38% GC patients [5].
The recent phase III ToGA trial involving 3,800 GC pa-
tients indicated that the combination of trastuzumab and
chemotherapy in Her2+ GC patients led to a significantly
higher overall response rate (ORR), 47% versus 35%, sig-
nificantly longer progression free survival (PFS) interval,
6.7 months versus 5.5 months, and significantly longer
OS duration, 13.8 months versus 11.1 months compared
to the chemotherapy arms respectively [6]. This positive
result led to the approval of trastuzumab as the first
molecularly targeted therapeutic agent for GC in both
the U.S. and Europe.
AKT is a serine/threonine protein kinase that plays a
central role in the signaling network involving PI3K and
mTOR, and which regulates multiple cellular processes
including glucose metabolism, apoptosis, cell prolifera-
tion, transcription and cell migration. Under normal
conditions, this signaling network can be activated by
many receptors, including members of the epidermal
growth factor receptor (EGFR) and vascular endothelial
growth factor receptor (VEGFR) families and their li-
gands. The activation of the PI3K/AKT/mTOR signaling
network has been commonly observed in many human
cancers, and can be triggered by a variety of mechanisms
including overexpression of upstream receptors, activat-
ing PI3KCA mutations, loss of PTEN function, and
overexpression or activation of AKT [5]. For instance,
the increased phosphorylations of AKT and mTOR have
been observed in 80% of [7] and 47%–64% of GC pa-
tients [7-10]. Further investigations have demonstrated
that the activation of the AKT/PI3K network can be at-
tributed to overexpression of upstream receptors (20%–
30%), PI3KCA activating mutations (4%–36%) [11,12]
and PTEN loss (20%–36%) [11,13]. A recent study by
Linos et al indicated that PTEN was lost in the majority
of Her2 positive GC cases [14]. These observations pro-
vide a possible explanation for the observed clinical resist-
ance of Her2 positive breast cancer patients to current
anti-Her2 therapies, including Trastuzumab and lapatinib.
This also suggests a rationale for the design of new com-
bination therapies through dual targeting of the Her2 and
PI3K–Akt–mTOR networks. Besides the involvement in
resistance to anti-Her2 therapies, the importance of the
PI3K–Akt–mTOR network in the resistance to chemo-
therapies in GC has been documented by a number of
studies [12,15]. In one such study, reduction of basal AKT
activity by ectopic expression of PTEN sensitized GC cells
to anti-cancer chemotherapy agents. When primary tumor
tissues from GC were tested for their chemotherapeutic
sensitivity in vitro, the association between activated AKTand increased resistance to multiple chemotherapeutic
agents including 5-fluorouracil, doxorubicin, mitomycin
C, and cisplatin was found [16].
We previously reported the development of a novel
AKT kinase inhibitor AZD5363, and found that cells
with both PI3KCA mutation and PTEN loss were highly
sensitive to treatment using AZD5363 [17]. In this study,
we further investigated the correlation between the
sensitivity of a panel of gastric cell lines to AZD5363
in vitro and their genetic aberrations. Using PDGCX
models derived from patient GC tissues, we further
confirmed a role for PI3KCA activating mutations and
PTEN loss in sensitizing tumors to AKT inhibition.
Materials and methods
Cell culture reagents, and proliferation assay
Human GC cell lines PAMC82 cells were obtained from
Beijing tumor hospital (Beijing, China). GTL-16, 23132/
87 cells were provided by AztraZeneca tissue culture
unit (Alderley Park, UK). NCI-N87, SNU-1, SNU-5, SNU-
16, HS746T and AGC were purchased from American
type culture collection (ATCC, American). KATOIII and
HGC27 were obtained from Europe collection of Cell Cul-
tures (ECACC, UK). NUGC-4, IM95 m, MKN-1, OCUM-
1, MKN-74, AZ-521 cells were obtained from Japanese
Collection of Research Bioresources Cell Bank (JCRB,
Japanese). NUGC-3 cells were obtained from Beijing Uni-
versity (Beijing, China). SNU-261, SNU-484, SNU-601,
SNU-620, SNU-638 and SNU-668 cells were obtained
from Korean cell line bank. IM95 m and HS746T cells
were cultured in DMEM medium with 10% FBS and
10 ug/ml insulin. OUCM-1 cells were cultured in
DMEM medium containing 10% FBS and 1% Na Pyru-
vate. All other cells were maintained in RPMI 1640
(Invitrogen) supplemented with 10% FBS and 2 mM L-
Glutamine. All cells were maintained in a humidified
incubator with 5% CO2 at 37°C. The structure and
synthesis of AKT inhibitor AZD5363 [(S)-4-amino-N-
[1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo [2,
3-d]pyrimidin 4-yl)piperidine-4-carboxamide has been
described previously [17].
Cell growth rate was measured by a MTS assay. Briefly,
cells seeded at 1000-2000/well density in 96 well plates
were cultured overnight, and then treated with AZD5363
at different concentrations for 72 hrs. CellTiter 96® Aque-
ous One Solution Reagent (Promega, Madison, WI) was
added to each well according to the manufacturer’s in-
structions. After 2 hours in culture the cell viability was
determined by measuring the absorbance at 490 nm using
Safire 2 plate-reader (Tecan, Switzerland).
Patients and tumor samples
The present study included 116 patients with GC who
underwent surgery between 2007 to 2011 at the Renji
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ical surgical resection, followed by standard chemother-
apy for the majority of the patients. Histologic subtype
according to Lauren’s classification was determined after
a review of tumor sections by two trained pathologists.
This study was approved by the institutional review
board at Renji Hospital.
Tissue microarray construction
GC tissue samples were fixed in buffered 4% formalin
for a minimum of 24 hours and embedded in paraffin.
The construction of tissue microarray (TMA) follows
standard procedures as previously described [18].
Immunohistochemistry (IHC)
The slides were baked at 56°C for 1 hour, then de-
paraffinized in xylene and hydrated through graded
series of alcohols. Antigen retrieval was done in pressure
cooker for 5 min using Citrate pH6, Target Retrieval
Solution (Dako, Glostrup, Denmark). After cooling to
room temperature, endogenous peroxidase activity was
blocked by Peroxidase Blocking Reagent (Dako) for 5 mi-
nutes. The sections were then incubated with rabbit
monoclonal antibody against PTEN (Cell Signaling Tech-
nology, USA) for 1 hour at room temperature. Then the
secondary anti-rabbit antibody (Dako, Envision) was ap-
plied to the sections for 30 minutes at room temperature.
After rinsed with TBST, the slides were treated with DAB
substrate-chromagen (Dako), counterstained with haema-
toxylin, dehydrated and mounted with coverslips. Scoring
was established as follows: 0, if absence of staining was ob-
served; 1+, if the tumor cells had weak staining; 2+, if
tumor cells had moderate staining; and 3+ if tumor cells
had strong staining. Tumors with 1+, 2+, and 3+ expres-
sion were interpreted as positive and tumors with no ex-
pression (0 score) were interpreted as negative. Given the
heterogeneity of protein expression in tumor cells, the
highest scoring from either one of TMA cores was counted
as the final result. To minimize impact of intratumoral het-
erogeneity, case-matched whole sections of negatively-
scored patient TMA samples were re-evaluated by IHC.
All slides were independently evaluated by two pathologists
(X. Y. and L. Z.) who are blind to patients’ clinical data.
The two pathologists discussed and reached final consen-
sus result for each case.
Western blot analysis
Frozen tumor fragments were homogenized in liquid ni-
trogen using a mortar and pestle and then lysed in RIPA
buffer (Pierce, #89901) containing Halt protease & phos-
phatase inhibitor cocktail (Pierce,78447). Soluble pro-
teins were quantified by BCA protein level detection kit
(Pierce,#23227 ), then soluble proteins (80 μg) subjected
to SDS-PAGE followed by immunoblotting. Antibodyincubation was conducted overnight at 4°C. Antibodies
were obtained from the following sources: phosphor-Akt
(S473) (Dako, cat.M3628), phosphor-PRAS40(Tyr436)
(Cell Signaling Technologies, cat.2997), Phospho-S6 Ribo-
somal protein (Ser235/236) (Cell Signaling Technologies,
cat.2211), AKT (Cell Signaling Technologies, cat.9272),
PRAS40(Cell Signaling Technologies, cat.2610), S6 Ribo-
somal Protein (54 D2) (Cell Signaling Technologies,
cat 2317), and GAPDH (Cell Signaling Technologies,
cat.2118). Secondary antibodies were applied and immu-
noreactive proteins were visualized using “SuperSignal
West Dura” Extended Duration Substrate according to the
manufacturer’s instructions (Thermo, #34076).
Sanger sequencing
PCR was performed in a 25 μL reaction mix containing
1× AmpliTaq Gold® 360 Master Mix (Life Technologies),
200 μM of each primer, and 5 μL of genomic DNA.
PI3K, Braf and Kras genes were amplified using the fol-
lowing primers: PI3KCA exon 10 forward 5′-GTCTTA
GATTGGTTCTTTCCTG-3′, PI3KCA exon 10 reverse
5′-GCATTTAATGTGCCAACTACC-3′; PI3KCA exon
21 forward 5′- TTTGTCTACGAAAGCCTCTCTA-3′,
PI3KCA exon 21 reverse 5′- CCATCACTTTTTCCTTC
TCCAT-3′. Braf exon 15 forward 5′- TTCATAATGCT
TGCTCTGATAGGAAAATG-3′, Braf exon 15 reverse
5′- GAACACTGATTTTTGTGAATACTGGGAACT-3′,
and Kras exon 2 forward 5′- GTACTGGTGGAGTAT
TTGATAGTG-3′, Kras exon 2 reverse 5′-GAGAGTGA
ACATCATGGACCCTG-3′. The PCR cycling conditions
were: 10-min incubation at 95°C, followed by 40 cycles of
94°C for 30 s, 60°C for 30 s, 72°C for 60 s, and then a final
incubation at 72°C for 10 min. The resulting PCR prod-
ucts were digested with ExoSAP-IT reagent (Affymetrix,
Cleveland, Ohio, USA), and then sequenced in forward
and reverse directions with BigDye Terminator Kit (Life
Technologies) and an ABI 3730XL DNA analyzer (Life
Technologies) following the manufacturer’s instructions.
The sequencing data were analyzed for mutations after as-
sembly and quality calling with SeqScape sequence ana-
lysis software (version 2.5; Life Technologies).
Allele specific polymerase chain reaction (ASPCR)
Human PI3K Gene Mutation Fluorescence Polymerase
Chain Reaction (PCR) diagnostic kit (Amoy Diagnostics,
Xiamen, China) was used for the Pi3KCA mutation detec-
tion in this study. This kit detects the 5 most common
Pi3KCA mutations: E542K, E545D, E545K, H1047R,
H1047L. All experiments were performed following the
manufacturer’s instructions. Briefly, 5 μL DNA was added
to 45 μL of the PCR master mix for each assay, which
contained PCR primers, fluorescent probes, PCR buffer,
and DNA polymerase. The PCR cycling conditions were:
5-min incubation at 95°C, followed by 15 cycles of 95°C
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93°C for 25 s, 60°C for 35 s, 72°C for 20 s. Fluorescent sig-
nal was collected from FAM and HEX channels. Geno-
types were determined according to threshold cycles (Ct)
as indicated in the manufacturer’s instructions.
Array comparative genomic hybridization (aCGH)
DNA was extracted using the QIAamp DNA Mini Kit
(Qiagen) according to the manufacturer’s instructions.
Array comparative genomic hybridization (aCGH) ana-
lysis was performed using the Agilent Human Genome
244 K Microarray Chip (Agilent Technologies) with
pooled human genomic DNA (Promega) as a reference.
Labeling, hybridization, washes, and data analysis were
performed according to the protocol provided by Agilent
(Protocol version 4.0, June 2006). Graphical overviews
were obtained using the CGH Analytics software (ver-
sion 3.5, Agilent Technologies).
Multiplex ligation-dependent probe amplification (MLPA)
MLPA assay was carried out according to the manufac-
turer’s instructions with the PTEN kit P225-A1 (MRC-
Holland, Netherlands). Fragment analysis was performed
with 1 μl MLPA PCR products by caplillary electrophor-
esis on an ABI3730XL DNA analyzer and analyzed using
Genotyper software v4.0 (Life technologies, USA). Each
exon copy number of PTEN was determined by calculat-
ing ratio of normalized test and control peak heights in
each run.
In vivo efficacy studies using patient-derived GC
xenograft (PDGCX) mouse models
Eight- to 10-week-old female nude (nu/nu) mice (Vital
River, Beijing) were used for development of PDGCX
mouse models and in vivo efficacy studies. All experi-
ments using immunodeficient mice were carried out in
accordance with the guidelines approved by Institutional
Animal Care and Use Committees (IACUC). PDGCX
mouse models were established by directly implanting
fresh surgical tumor tissue into immunodeficient mice.
Prior written informed consents were obtained from all
patients who contribute his/her tumor tissues and the
study protocol was approved by the local hospital ethics
committee. After establishment and characterization of
PDGCX models, PDGCX tissues were harvested and fro-
zen in medium with 90% serum and 10% DMSO in liquid
nitrogen. For the anti-tumor efficacy studies, PDGCX
tissue fragments (~15 mm3) were implanted subcutane-
ously via Trocar needle into female nude mice subcutane-
ously. Tumor-bearing mice with a tumor size range of 100
to 200 mm3 were randomly divided into control and
treatment groups (8 animals per group) for treatment.
AZD5363 was solubilized in 10% DMSO 25% w/v Kleptose
HPB (Roquette) buffer and dosed by oral gavage. Taxotere(Sanofi-Aventis) solubilized in 2.6% ethanol was adminis-
trated by intravenous injection once weekly. For the com-
bination treatment, Taxotere was injected one hour in the
PDGCX model before the oral dose of AZD5363. The con-
trol group received the DMSO/Kleptose buffer alone, twice
daily by oral gavage. Subcutaneous tumors in nude mice
and mouse body weight were measured twice weekly.
Tumor volumes were calculated by measuring 2 perpen-
dicular diameters with calipers [formula: V = (length ×
width2)/2]. Percentage tumor growth inhibition [%TGI = 1-
(change of tumor volume in treatment group/change of
tumor volume in control group) × 100] was used for the
evaluation of antitumor efficacy. Statistical significance was
evaluated using a one-tailed, two-sample t test. P < 0.05
was considered statistically significant.
Results
GC cells harboring PI3KCA mutations were selectively
sensitive to the AKT inhibitor AZD5363
To explore the potential application of AZD5363 in GC,
a panel of 22 GC lines was tested for anti-proliferative
sensitivity using an in vitro cell growth assay. Cells
seeded in 96 well plates were cultured overnight, and
then treated with AZD5363 at different concentrations
for 72 hrs. Cell growth rate was measured by a MTS
assay. As shown in Table 1, 6 out of the 22 tested cell
lines displayed sensitivity to AZD5363 with IC50’s lower
than 3 μM [17]. Further analysis of the known genetic
lesions in the GC cell panel indicated that 4 of the sensi-
tive cell lines harbored the PI3KCA E542K mutation, one
of the major PI3KCA activating mutations reported previ-
ously [19]. Interestingly, HGC27, the most sensitive line
amongst the 4 PI3KCA mutant cell lines, contained not
only PI3KCA mutation, but also PTEN loss. As we
reported recently [17], when nude mice bearing HGC27
xenograft tumors were treated with AZD5363, complete
tumor regression was achieved. Together, these data sug-
gest that activation of the PI3K/AKT pathway by PI3KCA
mutations or PTEN loss drives tumorigenesis in GC, po-
tentially defining a new molecular segment for AKT-based
targeted therapies.
Prevalence of PI3KCA mutations and PTEN loss in Chinese
GC
Next we sought to identify GC patients with both PI3KCA
mutations and PTEN loss, who will benefit the most from
AZD5363 therapy. The hotspot mutations of PI3K, Braf
and Kras genes and loss of PTEN was screened in a cohort
of 150 Chinese GC samples by using mutation specific
PCR and IHC respectively. As shown in Table 2, PI3KCA
mutations were identified in the samples from 4 patients
(3 with grade 3 and 1 with grade 2 diseases), representing
a mutation rate of 2.7% (4/150). Besides PI3K activation
through mutation, loss of PTEN represents another
Table 1 AZD5363 inhibits proliferation of a subset of GC
cell lines in vitro
Cell line Genetic background GI50 (μmol/L)
PIK3CA PTEN
HGC27 E542K LOSS 0.445
IM95m E452K WT 0.510
AGS E453K WT 0.552
NCI-N87 WT WT 1.037
23132/87 WT WT 1.671
MKN1 E545K WT 2.421
SNU-620 WT WT 3.384
SNU-638 WT WT 4.523
SNU-1 WT WT 5.258
SNU-601 WT WT 5.938
SNU-668 WT WT 6.003
HS746T WT WT 6.084
KATO III WT WT 7.267
SNU-484 WT WT 7.392
SNU-16 WT WT 11.097
OCUM-1 WT WT 14.515
NUGC-3 WT WT 21.873
AZ521 WT WT 25.448
SNU-216 WT WT 30.000
NUGC-4 WT WT 30.000
SNU-5 WT WT 30.000
GTL-16 WT WT 30.000
MKN74 WT WT 30.000
PAMC82 WT WT 30.000
A panel of GC cell lines with differing genetic backgrounds were screened in a
standard MTS cell proliferation assay. The PI3KCA mutation and PTEN
expression status were determined by ASPCR and IHC respectively.
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become activated. Thus, we also investigated the expres-
sion status of PTEN in GC. A total of 61 qualified tumor
samples from the same cohort of Chinese GC were exam-
ined by IHC staining using an anti-PTEN antibody. As
shown in Table 2 and Figure 1, the loss of PTEN protein
expression was found in 23% (14/61) of the tested sam-
ples, consistent with the reported rate of 20% [20]. Further
sequencing analysis of the 61 samples indicated that
PTEN loss overlapped with Braf mutation in one case, but
was mutually exclusive with PI3KCA and Kras mutations
(Table 3).Table 2 PI3KCA mutations and PTEN loss in Chinese GC
Mutation Assay Status (%)
PI3KCA (hot spots) ASPCR 2.7% (4/150)
PTEN loss IHC 23% (14/61)Anti-tumor efficacy of AZD5363 in gastric PDGCX mouse
models with PI3KCA mutation or PTEN loss
The lack of GC patients with both PI3KCA mutations
and PTEN loss and the high prevalence of PTEN loss
observed in GC triggered us to investigate the response
of GC with PTEN loss to AZD5363. However, due to
the lack of GC cell lines with PTEN loss and wild-type
PI3K, we screened 15 gastric PDGCX mouse models
established from surgical samples of Chinese GC pa-
tients. The expression levels of PTEN protein were mea-
sured by IHC staining and genomic PTEN aberrations
were detected by MLPA analysis respectively. PI3KCA
hotspot mutations were screened by direct sequencing.
As indicated in Table 4, SGC020, a PDGCX model with
a PTEN exon 2-6 gene deletion and undetectable PTEN
protein expression and SGC100, a PDGCX model har-
boring a PI3KCA H1047R activating mutation and posi-
tive PTEN staining, were both identified for AZD5363
anti-tumor efficacy study. As shown in Figure 2A, higher
levels of basal phosphor AKT and phosphor S6 were
detected by Western blot in SGC100 and SGC020
tumors compared to that in the SGC001 PDGCX tu-
mors with PI3K and PTEN wild-type status, indicating
the up-regulation of AKT signal pathway in SGC100 and
SGC020 models.
Next we tested the response of SGC100 and SGC020
models to AZD5363. As shown in Figure 2B and 2C,
AZD5363 single agent treatment resulted in 60% tumor
growth inhibition in SGC100 model (P < 0.0001) but had
only marginal effects (23% tumor growth inhibition,
p < 0.002) in the PTEN null SGC020 model. AZD5363
treatment in this study was well tolerated and did not
result in significant body weight loss. These data indicate
that PI3KCA mutations, but not PTEN loss, predicate
the sensitivity to AZD5363 in GC.
Chemotherapy is the current standard of care for GC.
In additional effort, we preformed in vitro combination
of AZD5363 with the commonly used chemotherapy
agents in GC including Taxotere, SN-38 and Oxaliplatin
in a number of GC cell lines with both PI3KCA muta-
tion and PTEN loss (HGC27), PI3KCA mutation alone,
and PI3K and PTEN wild-type status. Our data showed
that the combination of AZD5363 with Taxotere, SN-38
and Oxaliplatin resulted in additive or slightly synergistic
effect regardless of the mutation status in PI3K gene
(Additional file 1: Table S1).
Previous reports have suggested a role for PTEN loss
in chemotherapy resistance [15]. Therefore, we next
tested whether PTEN loss contributed to Taxotere resist-
ance, one of the major chemotherapy agents used clinic-
ally in GC [21]. As shown in Figure 2B, Taxotere at a
human equivalent dose of 5 mg/kg weekly had no effect
on tumor growth in the SGC020 model with PTEN loss.
In contrast, combinations of AZD5363 and Taxotere
A B
Figure 1 Representative images from PTEN IHC staining. (A). Positive PTEN staining was observed in the cytoplasm and nuclei of the tumor
cells (black arrow) and stroma cells (red arrow). (B). Negative PTEN staining in the tumor cells (black arrow) and positive staining in the
stroma cells.
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the PDGCX model, supporting a potential combination
strategy for the treatment of GC with PTEN loss. In
addition, the induction of caspase3/7 by combination of
AZD5363 with Taxotere, the hallmark of cell apoptosis,
was observed in multiple tested cell lines, suggesting the
anti-tumor effect of AZD5363 with Taxotere by induc-
tion of apoptotic cell death (Additional file 1: Table S1).
Pharmacodynamic modulation of AKT signaling by
AZD5363 correlates with anti-tumor activity
To understand the mechanism of AZD5363 anti-tumor
efficacy and its combination with Taxotere in SGC020
and SGC100 models, tumor samples were collected two
hours post-last dose of AZD5363. Tissues lysates wereTable 3 Genetic background of GC with PTEN loss












802204 (-) Wild type Wild type Wild type
1007947 (-) Wild type V600E Wild type
44256 (-) Wild type Wild type Wild type
34711 (-) Wild type Wild type n/a
608902 (-) Wild type Wild type Wild type
60077 (-) Wild type Wild type Wild type
606186 (-) Wild type Wild type n/a
803776 (-) Wild type Wild type Wild type
1007953 (-) Wild type Wild type Wild type
708053 (-) Wild type Wild type Wild type
708025 (-) Wild type Wild type n/a
16627 (-) Wild type Wild type n/a
505496 (-) Wild type Wild type n/a
508745 (-) Wild type Wild type Wild type
600460 (+) E542K/E545D* Wild type n/a
802664 (+) Wild type Wild type G12D*
*The PI3KCA and KRAS mutations were mutually exclusive from PTEN loss.subjected to Western blot analysis of PRAS40 and S6
phosphorylation, both downstream targets of AKT signal-
ing. As shown in Figure 3, AZD5363 single agent treat-
ment led to up-regulated pAKT in both SGC100 and
SGC020 PDGCX models, indicating the engagement of
AZD5363 with its specific target [17]. It is noteworthy that
the undetectable pAKT (S473) in the untreated SGC100
and SGC020 tumors was due to a shorter western blot
exposure since very strong signals were detected in the
AZD5363 treated samples. Interestingly, the suppression
of AKT downstream signaling monitored by pPRAS40
(52%) and pS6 (42%) was only observed in the PI3KCA
mutant PDGCX model (SGC100), but not in the PTEN
null PDGCX model (SGC020), correlating with AZD5363
anti-tumor efficacy. Consistent with our recent observa-
tions in cell cultures (data not shown), Taxotere treatment
led to a moderate increase of pPRAS40 (Figure 3C/3D) in
SGC20 model and the addition of AZD5363 blocked this
induction. These results further support the activation of
AKT signaling as a resistance mechanism to chemother-
apy agents, and strongly suggest AKT inhibition as a vi-
able sensitization approach.
Discussion
Emerging evidence supports a critical role for the activa-
tion of the PI3K/AKT signaling network in both tumori-
genesis and drug resistance. A number of novel small
molecule inhibitors targeting PI3K, AKT and mTOR are at
different stages of drug development for the treatment of a
variety of solid tumors, including GC [22]. Everolimus, an
mTOR inhibitor approved for breast cancer, neuroendo-
crine tumors of pancreatic origin and subependymal giant
cell astrocytoma, has been tested in GC patients in a phase
II and phase III trial. In the recent phase II trial, everolimus
demonstrated anti-tumor activity with a response rate of
3.7% (2/44) and disease control rate (DCR) of 38.9% (17/
44) [23]. Although the trial failed to achieve its primary ob-
jective (30% of 4-month progression-free survival (PFS)
rate), the observed association between high expression of
Table 4 Characterization of PDGCX mouse models
Model ID Her2 amp PTEN analysis PI3KCA
mutation
aCGH MLPA IHC Sequencing
SGC020 (-) Exon2-6 deletion (-) Wild-type
SGC100 (-) N/A 70% ++ (C&N) H1047R
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PFS warrant further trials with a molecular stratification-
based patient selection strategy.
Recently we reported the development of AZD5363, a
potent pan-AKT kinase inhibitor, which is currently
undergoing phase I clinical investigation. Our previous re-
sults demonstrated that cancer cells harboring PI3KCA
activating mutations, PTEN mutations (loss or mutations),
or Her2 amplification were highly sensitive to AZD5363
[17]. This sensitivity was further confirmed in several
xenograft tumor models. Interestingly, we found that
HGC27, a GC cell line with PI3KCA mutation and PTEN


























Figure 2 AZD5363 treatment results in significant inhibition in PDGC
and SGC020 PDGCX models. The basal levels of phosphor AKT (S473) and p
blot analysis. (B). Anti-tumor efficacy of AZD5363 monotherapy in SGC100
daily to nu/nu mice bearing established PDGCX SGC100 model with PI3KC
monitored and plotted against time. (C) Anti-tumor efficacy of AZD5363 in
administered by oral gavage twice (bid) daily to nu/nu mice bearing estab
combination with Taxotere at 5 mg/kg weekly. Tumor volumes were moniboth in vitro and in vivo. Because PTEN loss is more
prevalent than PI3KCA mutations and the frequency of
these concurrent aberrations is very low, it is intriguing to
understand whether the loss of function of PTEN alone is
sufficient to drive the response to AKT inhibition.
PTEN phosphatase is a novel tumor suppressor and
negatively regulates the PI3K/Akt signaling network [24].
PTEN functional loss can be attributed to inactivating
gene mutations, chromosomal deletions and promoter
methylation, all of which are implicated in multiple cancer
types including GC [25]. In comparison to PI3KCA muta-
tions, the lack of detectable PTEN protein expression by
IHC staining was more frequently observed in GC with
reported rates of between 20-36% [11,13]. However, the
role of PTEN in driving cancer development and the re-
sponse to agents targeting the PI3K/AKT pathway is yet
to be fully understood. In this report, we screened 15
primary xenograft models derived from primary GC tu-
mors and identified one model with PI3KCA activating
mutation and another with undetectable PTEN expres-
























AZD5363 150 mg/kg/bid p.o
Taxotere 5 mg/kg once weekly
AZD5363 150 mg/kg/bid p.o + Taxotere 








X mouse models. (A). Activation of AKT signaling pathway in SGC100
hosphor S6 (S235/236) in PDGCX tumors were measured by Western
PDGCX model. AZD5363 was administered by oral gavage twice (bid)
A mutant tumors at 150 mg/kg single agent. Tumor volumes were
combination with Taxotere in PDGCX SGC020 model. AZD5363 was
lished PDGCX SGC020 model with PTEN null tumors at 150 mg/kg in




















































































Figure 3 Pharmacodynamic study of tumors treated with AZD5363 or in combination with Taxotere. (A) and (B). Suppression of AKT
downstream signalling by AZD5363 in SGC100 PDGCX tumors with PI3KCA muttion. The tumor bearing mice were treated with AZD5363
(150 mg/kg, bid) for 25 days. Tumors samples were collected two hours post-final dose and were subjected to western blot analysis for phospho-
AKT (S473), phospho-PRAS40 (T246) and phosphor S6 (A). The expression levels were quantified by gel imaging scan and expressed as mean +
SD (B). (C) and (D). Mudulation of AKT downstream signalling by AZD5363 and Taxotere in SGC020 PDGCX tumors with PTEN loss. The tumor
bearing mice were treated with AZD5363 (150 mg/kg, bid) in combination with Taxotere (5 mg/kg weekly) for 25 days. Tumors samples were
collected two hours post-final dose and were subjected to western blot for phospho-AKT (S473), phospho-PRAS40 (T246) and phosphor S6 (C).
The expression levels were quantified by gel imaging scan and expressed as mean + SD (D). Students’ t-tests were used to compare modulation
in the treatment group with the control group. Statistical tests were two sided, with P < 0.05 considered significant (*).
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model, consistent with the cell panel data. In contrast, no
significant efficacy was observed in the PDGCX model
with PTEN loss, suggesting a minor role for PTEN loss
in driving tumorigenesis in GC. However, when a PTEN
null PDGCX model was treated with a combination of
AZD5363 and taxotere, a synergistic effect was achieved
compared to treatment with either single agent. This is
consistent with previous observations by us and others
[17,26]. In the Her2 positive BT474 model, a combin-
ation of AZD5363 with Taxotere led to complete tumor
regression. Similarly, Lin et al showed that administra-
tion of another AKT kinase inhibitor, GDC-0068, in
combination with Taxotere induced tumor regression in
the PC-3 prostate xenograft model with a homozygous
deletion of PTEN, at doses where each single agent only
caused modest tumor growth delay. To further under-
stand the underlying molecular mechanism for the
combination effect in the PTEN null PDGCX model
(SGC020), pAKT modulation and downstream signalingwas studied. Consistent with previous observations, in-
creased AKT phosphorylation was observed following
AZD5363 treatment, suggestive of target engagement.
However, we did not observe anti-tumor efficacy using
AZD5363 monotherapy, nor modulation of pPRAS40 and
S6. The reason for the inability of single agent AZD5363
to elicit efficacy in a PDGCX model (SGC020) is not cur-
rently fully understood. As the tumor samples used for
the pharmacodynamic study were collected after a mul-
tiple dosing regimen, we postulate that there may be dy-
namic subtleties within the AKT signaling pathway and
that further study using a single dose of AZD5363 over a
dynamic time course may provide additional insight.
Consistent with our own results from cell culture stud-
ies (data not shown), the expression levels of pPRS40
and pS6 were moderately upregulated by Taxotere in a
PDGCX SGC020 model and treatment with AZD5363
blocked this activation, suggesting a possible mechan-
ism for the anti-tumor efficacy observed in the combin-
ation study.
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ously reported by several groups. Mutation frequencies
range from 10.6%% to 15.9% [27,28] in Caucasian and
4.3% to 7.1% in Asian GC [12,29]. This apparent dis-
crepancy between Western and Eastern populations may
be due to geographical differences, as shown for the situ-
ation with EGFR mutation in lung cancer [30]. In a sep-
arate study we found that the mutations in a number of
oncogenes, including PI3KCA mutations, are enriched
in advanced stage and genomically unstable patients
(manuscript in preparation). The low frequency (2.7%, 4/
127) of PI3KCA mutation detected in our study may be
due to the relatively small sample size related to disease
stage and genomic instability status.
The observations described in this study were supported
by emerging data from our ongoing two AZD5363 phase I
clinical trials [31]. As a monotherapy, AZD5363 was gen-
erally well tolerated when administrated using intermit-
tent doses of 480 mg twice daily, with four days on and
three days off. The pharmacokinetic studies indicated that
exposures achieved in patients were comparable to those
achieved at efficacious doses used in our preclinical
animal studies. Reductions in pPRAS40 and pGSK3β in
plucked hair and blood samples were observed in 30% of
patients. To date, partial responses have been observed in
two treated patients, harboring tumor mutations in either
AKT1 or PI3KCA. Given the high prevalence of PTEN
loss in gastric cancer, the synergistic combination effect of
AZD5363 with Taxotere in the PTEN-loss primary model
warrants further clinical trial for potential application of
AKT inhibitors for the treatment of patients with PTEN
null tumors.
In conclusion, AZD5363, a potent and selective small
molecule AKT inhibitor, demonstrates the effectiveness
to suppress growth of PI3KCA mutant GC cells in vitro
and PDGCX model in vivo. It reverses the de novo resist-
ance to Taxotere in a PTEN loss PDGCX model. These
results point out a potential new strategy for treatment of
subsets of GC patients with AKT inhibitors.
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